Methods and Results. The effect on forearm blood flow of intra-arterial NPY was studied in six volunteers during coinfusion of noradrenaline and during reflex sympathetic stimulation induced by lower-body negative pressure. NPY alone induced a dose-dependent reduction of forearm blood flow in all subjects studied, to a maximum of 49+6.1%. The reduction of flow during infusion of noradrenaline alone was 42±8%. The response to noradrenaline was unaffected by coinfusion of a threshold constrictor dose of NPY (50 pmol/min). Furthermore, the reflex sympathetic vasoconstrictor response to 20 cm H20 of lower-body negative pressure was similar in both the infused and control arms during the infusion of 50 pmol/min NPY. The response to noradrenaline was abolished by a-blockade with phentolamine, but the flow reduction induced by NPY was unaffected by a-blockade.
Conclusions. NPY is a potent constrictor of human forearm resistance vessels and has a direct effect independent of a-receptors. NPY has no detectable modulating effect in vivo on A 27-gauge unmounted steel cannula was inserted into the nondominant (left) brachial artery using local anesthesia (1% lidocaine hydrochloride). Solutions were infused at a constant rate of either 0.5 or 1.0 ml/min throughout the experiment by means of a constant-rate infusion pump (944A, Harvard Apparatus, South Natick, Mass.). When two drugs were infused simultaneously, a Y-connector delayed mixing until the solutions entered the cannula. The dominant arm was not cannulated and served as a control. Each study took place in the morning, after the volunteers had rested supine in a quiet clinical laboratory for a minimum of 30 minutes at a room temperature maintained between 260 and 28°C. Saline (0.9% NaCl, Travenol Laboratories, Deerfield, Ill.) was infused for 10 minutes, followed by infusion of three incremental doses of freshly reconstituted NPY (50, 200, and 1,000 pmol/min, Peninsula Laboratories, Inc., Belmont, Calif.), each given for 6 minutes. Forearm blood flow was measured during the last 3 minutes of each infusion, and measurements continued at intervals for up to 20 minutes after stopping the NPY infusion. The 10-minute saline infusion was repeated, followed by infusion of incremental doses of noradrenaline (125, 250, and 500 pmol/min), each given for 6 minutes. Forearm blood flow was measured during the final 3 minutes of each infusion. After 20 minutes, the infusions of noradrenaline were repeated during coinfusion of 50 pmol/min NPY.
In each subject a lower-body negative-pressure chamber constructed of polyethylene sheeting over a reinforced mesh wire framework was placed around the lower portion of the body from the iliac crest down.10 A seal was formed between the walls of the chamber and the subject using adhesive tape. An adjustable vacuum pump was connected to the sealed chamber, and the negative pressure achieved was measured continuously using a water manometer. Saline, 50 pmol/min NPY, and saline were sequentially infused during three consecutive 12-minute periods. During each period, forearm blood flow was measured continuously after the third minute. From the sixth to the ninth minutes lower-body negative pressure was applied to a degree (20 cm H2O) that has been shown to have no effect on blood pressure and heart rate.10
In four subjects 500 pmol/min noradrenaline and then 1,000 pmol/min NPY were infused for 6 minutes each, followed by an interval of 10 minutes to allow blood flow to return to baseline. Phentolamine (300 nM/min) alone was then infused for 20 minutes, at which time noradrenaline was added to the phentol- amine infusion. Following cessation of the noradrenaline infusion, NPY was infused during continued infusion of phentolamine. Blood flow was measured during the last 3 minutes of each infusion.
Student's t test for paired observations was used for statistical analysis, and the data are presented as mean±SEM.
Results NPY reduced forearm blood flow in a dose-dependent fashion in all six subjects (Figure 1 ). The lowest dose (50 pmol/min) induced slight reduction in some subjects, but the overall effect was not significant. At the peak dose, blood flow was reduced from 3.8±0.6 to 1.8±0.2 ml/100 ml/min. At this dose, the effect of NPY was detectable within 2 minutes of commencing the infusion and persisted for up to 15 minutes after stopping the infusion. Blood flow in the control arm showed no consistent change during the study.
Noradrenaline also reduced forearm blood flow in all subjects in a dose-dependent fashion (Figure 2 , left), from 4.8±1.1 to 2.5±0.4 ml/100 ml/min. This response was unaffected by coinfusion of 50 pmol/ min NPY (Figure 2, right and blood flow returned to basal values within 5 minutes of stopping the infusion. Lower-body negative pressure reduced forearm blood flow in both arms, by 14.0±3% during saline infusions and by 20.3±3.0% during NPY infusion (differences not significant, Figure 3) . While there was a trend toward enhanced reflex flow reduction during NPY infusion in both arms, this did not reach the level of significance.
A single dose of 1,000 pmol/min NPY resulted in a reduction in blood flow similar to that induced by 500 pmol/min noradrenaline. Coinfusion of phentolamine caused an increase in basal forearm blood flow and abolished the response to noradrenaline, but the response to NPY remained unchanged and was undiminished ( Figure 4 ). Discussion We examined the effects on the human forearm vascular bed of intra-arterial administration of NPY. At low concentrations, this peptide caused a large dose-dependent reduction in blood flow very similar to that demonstrated by Pernow et al. 11 Previous studies have shown three possibly distinct actions of NPY in vitro using animal tissue: presynaptic inhibition of noradrenaline release, postsynaptic potentiation of noradrenaline's action, and a direct action independent of a-adrenergic receptors. The failure of the nonselective a-blocking agent phentolamine in these circumstances to diminish or abolish the constrictor action of NPY is clear evidence of the existence of a direct mechanism of action in vivo in man.
While no significant enhancement of reflex constriction to lower-body negative pressure was found during NPY infusion, a small decrease in blood flow was observed in both arms, suggestive of a central effect of the small increment in the circulating NPY concentration.
The similarity of the pressor responses in the two arms to lower-body negative pressure suggests that the much higher local concentration of NPY was unable to directly modify sympathetic constriction in the peripheral circulation. This lack of potentiation of constriction, induced by either reflex or by infusion of noradrenaline, suggests that in the human forearm NPY acts directly rather than through presynaptic or postsynaptic augmentation of noradrenergic sympathetic function. This is in contrast to many in vitro studies that clearly demonstrate an indirect constrictor effect of NPY.6,8 It is possible that with intraluminal administration, the concentration of the peptide is relatively less on the adventitial side of the vessel, where the majority of the neuroeffector junctions are located. However, an enhanced sympathetic response to lower-body negative pressure has been documented with intraluminal administration of angiotension II and, therefore, accessibility of binding sites does not appear to be a limiting factor. 12 Compared with noradrenaline, NPY is slower to act but the constriction is longer-lasting. The response in the forearm was quite reproducible and similar in all subjects studied. This is in contrast to our'3 and other8 observations in the coronary bed and in vitro, where responses are variable and tend to be "all or nothing."
The reduction in forearm blood flow demonstrates the ability of NPY to produce constriction of resistance vessels, as has been demonstrated in the coronary circulation in dogs13 and humans14 and is consistent with the observation of more NPY-containing nerve vesicles in smaller arteries. 15 The observation that phentolamine fails to abolish the constrictor response to NPY is consistent with the documented failure of a-blockade to completely abolish the vascular effects of sympathetic stimulation in other models. ' 
